Yenidoğan Ensefalopatileri
Özet
Yenidoğan döneminde karşılaşılan metabolik ensefalopatiler; glikoz düzensizlikleri, hiperbilirübinemi ve çeşitli amino asit, üre döngüsü, organik asit veya yağ asidi oksidasyon bozukluklarını içeren kritik klinik tablolardır. Erken tanı konulmayan bu metabolik bozukluklar, geri dönüşümsüz nörolojik hasara, ciddi gelişimsel geriliğe ve yüksek mortalite riskine yol açabilir. Hastaların yönetimi; klinik bulguların titiz takibini, biyokimyasal taramaları ve vakaya özel diyet veya farmakolojik tedavi yöntemlerini kapsayan çok yönlü bir yaklaşım gerektirir.
Neonatal metabolic encephalopathies comprise critical clinical conditions including glucose dysregulation, hyperbilirubinemia, and various disorders of amino acid, urea cycle, organic acid, or fatty acid metabolism. These conditions can cause irreversible neurological damage, severe developmental impairment, and high mortality if not diagnosed and managed in the early postnatal period. Effective management relies on a multidisciplinary approach involving careful clinical monitoring, specific biochemical diagnostics, and targeted dietary or pharmacological interventions.
Referanslar
Cornblath M, Hawdon JM, Williams AF et al.Controversies regarding definition of neonatal hypoglycemia: suggested operational thresholds. Pediatrics. 2000;105(5):1141-5. doi: 10.1542/peds.105.5.1141. PMID: 10790476.
Garg M, Devaskar SU. Glucose metabolism in the late preterm infant. Clin Perinatol. 2006 ;33(4):853-70; abstract ix-x. doi: 10.1016/j.clp.2006.10.001. PMID: 17148009.
Hays SP, Smith EO, Sunehag AL. Hyperglycemia is a risk factor for early death and morbidity in extremely low birth-weight infants. Pediatrics. 2006;118(5):1811-8. doi: 10.1542/peds.2006-0628. PMID: 17079549.
Jagła M, Szymońska I, Starzec K, Kwinta P. Impact of early glycemic variability on mortality and neurologic outcome of very low birth weight infants: Data from a continuous glucose monitoring system. Dev Period Med. 2019;23(1):7-14. PMID: 30954975.
Auerbach A, Eventov-Friedman S, Arad I, Peleg O, Bdolah-Abram T, Bar-Oz B, Zangen DH. Long duration of hyperglycemia in the first 96 hours of life is associated with severe intraventricular hemorrhage in preterm infants. J Pediatr. 2013 ;163(2):388-93. doi: 10.1016/j.jpeds.2013.01.051. Epub 2013 Mar 6. PMID: 23472766.
Beltrand J, Busiah K, Vaivre-Douret L, Fauret AL, Berdugo M, Cavé H, Polak M. Neonatal Diabetes Mellitus. Front Pediatr. 2020 30;8:540718. doi: 10.3389/fped.2020.540718. PMID: 33102403; PMCID: PMC7554616.
Gurgel LC, Moisés RS. Diabetes melito neonatal [Neonatal diabetes mellitus]. Arq Bras Endocrinol Metabol. 2008 ;52(2):181-7. Portuguese. doi: 10.1590/s0004-27302008000200005. PMID: 18438528.
Stanley, C. A., & Pallotto, E. K. (2005). Disorders of carbohydrate metabolism. In H. W. Taeusch, R. A. Ballard, & C. A. Gleason (Eds.), Avery’s diseases of the newborn (8th ed., pp. 1410–1422). Philadelphia: Elsevier Saunders.
Gökşen Şimşek D, Ecevit A, Hatipoğlu N, et al. Neonatal Hyperglycemia, which threshold value, diagnostic approach and treatment?: Turkish Neonatal and Pediatric Endocrinology and Diabetes Societies consensus report. Turk Pediatri Ars 2018; 53(Suppl 1): S234-S238.
Whipple AO, Frantz VK. Adenoma of ıslet cells wıth hyperınsulınısm: a revıew. Ann Surg. 1935;101(6):1299-1335. doi:10.1097/00000658-193506000-00001
Hawdon JM. Identification and Management of Neonatal Hypoglycemia in the Full-Term Infant. British Association of Perinatal Medicine Framework for Practice, 2017. J Hum Lact. 2019 ;35(3):521-523. doi: 10.1177/0890334419846128. Epub 2019 May 3. PMID: 31051094.
Thompson-Branch A, Havranek T. Neonatal Hypoglycemia. Pediatr Rev. 2017 ;38(4):147-157. doi: 10.1542/pir.2016-0063. PMID: 28364046.
Hay WW Jr, Raju TN, Higgins RD, Kalhan SC, Devaskar SU. Knowledge gaps and research needs for understanding and treating neonatal hypoglycemia: workshop report from Eunice Kennedy Shriver National Institute of Child Health and Human Development. J Pediatr. 2009;155(5):612-617. doi:10.1016/j.jpeds.2009.06.044
. McGowan JE, Price-Douglas W, Hay WW. Glucose homeostasis. In: Merenstein GB, Gardner SL, eds. Handbook of neonatal intensive care. 6th ed. St Louis: Mosby Elsevier; 2006. p. 368-90.
Mitchell NA, Grimbly C, Rosolowsky ET et al. Incidence and Risk Factors for Hypoglycemia During Fetal-to-Neonatal Transition in Premature Infants. Front Pediatr. 2020 11;8:34. doi: 10.3389/fped.2020.00034. PMID: 32117839; PMCID: PMC7026247.
Harris DL, Weston PJ, Harding JE. Incidence of neonatal hypoglycemia in babies identified as at risk. J Pediatr. 2012 Nov;161(5):787-91. doi: 10.1016/j.jpeds.2012.05.022. Epub 2012 23. PMID: 22727868.
Duvanel CB, Fawer CL, Cotting J, Hohlfeld P, Matthieu JM. Long-term effects of neonatal hypoglycemia on brain growth and psychomotor development in small-for-gestational-age preterm infants. J Pediatr. 1999 ;134(4):492-8. doi: 10.1016/s0022-3476(99)70209-x. PMID: 10190926.
Adamkin DH. Neonatal hypoglycemia. Curr Opin Pediatr. 2016;28(2):150-5. doi: 10.1097/MOP.0000000000000319. PMID: 26780301.
Stanley CA, Rozance PJ, Thornton PS, De Leon DD, Harris D, Haymond MW, Hussain K, Levitsky LL, Murad MH, Simmons RA, Sperling MA, Weinstein DA, White NH, Wolfsdorf JI. Re-evaluating "transitional neonatal hypoglycemia": mechanism and implications for management. J Pediatr. 2015 Jun;166(6):1520-5.e1. doi: 10.1016/j.jpeds.2015.02.045. Epub 2015;25. PMID: 25819173; PMCID: PMC4659381.
Richard M. Cowett, Robert E. Rapoza, Nancy L. Gelardi, Insulin counterregulatory hormones are ineffective in neonatal hyperinsulinemic hypoglycemia, Metabolism, Volume 48, Issue 5, 1999, Pages 568-574, ISSN 0026-0495, https://doi.org/10.1016/S0026-0495(99)90052-5.
Aral YZ, Gücüyener K, Atalay Y, Hasanoğlu A, Türkyilmaz C, Sayal A, et al. Role of excitatory aminoacids in neonatal hypoglycemia. Acta Paediatr Jpn (1998) 40:303–6. doi: 10.1111/j.1442-200X.1998.tb01936.x
Sensi SL, Paoletti P, Koh JY, Aizenman E, Bush AI, Hershfinkel M. The neurophysiology and pathology of brain zinc. J Neurosci. 2011 9;31(45):16076-85. doi: 10.1523/JNEUROSCI.3454-11.2011. PMID: 22072659; PMCID: PMC3223736.
De Angelis LC, Brigati G, Polleri G, Malova M, Parodi A, Minghetti D, Rossi A, Massirio P, Traggiai C, Maghnie M, Ramenghi LA. Neonatal Hypoglycemia and Brain Vulnerability. Front Endocrinol (Lausanne). 2021 16; 12:634305. doi: 10.3389/fendo.2021.634305. PMID: 33796072; PMCID: PMC8008815.
Pan DH, Rivas Y. Jaundice: Newborn to Age 2 Months. Pediatr Rev. 2017;38(11):499-510. doi: 10.1542/pir.2015-0132. Erratum in: Pediatr Rev. 2017;38(12): 577. PMID: 29093118.
Preer GL, Philipp BL. Understanding and managing breast milk jaundice. Arch Dis Child Fetal Neonatal Ed. 2011;96(6):F461-6. doi: 10.1136/adc.2010.184416. Epub 2010. PMID: 20688866.
Bhutani VK, Johnson LH, Jeffrey Maisels M, Newman TB, Phibbs C, Stark AR, Yeargin-Allsopp M. Kernicterus: epidemiological strategies for its prevention through systems-based approaches. J Perinatol. 2004 ;24(10):650-62. doi: 10.1038/sj.jp.7211152. PMID: 15254556.
Slusher TM, Zamora TG, Appiah D, Stanke JU, Strand MA, Lee BW, Richardson SB, Keating EM, Siddappa AM, Olusanya BO. Burden of severe neonatal jaundice: a systematic review and meta-analysis. BMJ Paediatr Open. 2017 25;1(1): e000105. doi: 10.1136/bmjpo-2017-000105. PMID: 29637134; PMCID: PMC5862199.
Kuzniewicz MW, Escobar GJ, Newman TB. Impact of universal bilirubin screening on severe hyperbilirubinemia and phototherapy use. Pediatrics. 2009 ;124(4):1031-9. doi: 10.1542/peds.2008-2980. Epub 2009 PMID: 19786442; PMCID: PMC2858633.
Rodrigues CM, Solá S, Brites D. Bilirubin induces apoptosis via the mitochondrial pathway in developing rat brain neurons. Hepatology. 2002;35(5):1186-95. doi: 10.1053/jhep.2002.32967. PMID: 11981769.
Watchko JF, Tiribelli C. Bilirubin-induced neurologic damage--mechanisms and management approaches. N Engl J Med. 2013;369(21):2021-30. doi: 10.1056/NEJMra1308124. PMID: 24256380.
Silva SL, Vaz AR, Barateiro A, Falcão AS, Fernandes A, Brito MA, Silva RF, Brites D. Features of bilirubin-induced reactive microglia: from phagocytosis to inflammation. Neurobiol Dis. 2010;40(3):663-75. doi: 10.1016/j.nbd.2010.08.010. Epub 2010. PMID: 20727973.
Kuzniewicz MW, Wickremasinghe AC, Wu YW, McCulloch CE, Walsh EM, Wi S, Newman TB. Incidence, etiology, and outcomes of hazardous hyperbilirubinemia in newborns. Pediatrics. 2014;134(3):504-9. doi: 10.1542/peds.2014-0987. Epub 2014. PMID: 25092943.
Christensen RD, Lambert DK, Henry E, Eggert LD, Yaish HM, Reading NS, Prchal JT. Unexplained extreme hyperbilirubinemia among neonates in a multihospital healthcare system. Blood Cells Mol Dis. 2013;50(2):105-9. doi: 10.1016/j.bcmd.2012.10.004. Epub 2012. PMID: 23123126.
American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004 ;114(1):297-316. doi: 10.1542/peds.114.1.297. Erratum in: Pediatrics. 2004 Oct;114(4):1138. PMID: 15231951.
Stevenson DK, Maisels MJ, Watchko JF, editors. Care of the jaundiced neonate. New York: McGraw Hill; 2012.
Kemper, A. R., Newman, T. B., Slaughter, J. L., Maisels, M. J., Watchko, J. F., Downs,et al.(2022) Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. Pediatrics, e2022058859. Advance online publication. https://doi.org/10.1542/peds.2022-058859
Çoban A, Kaynak Türkmen M, Gürsoy T. Turkish Neonatal Society guideline to the approach, follow-up, and treatment of neonatal jaundice. Turk Pediatri Ars 2018; 53(Suppl 1): S172-S179.
Johnson LH, Bhutani VK, Brown AK. System-based approach to management of neonatal jaundice and prevention of kernicterus. J Pediatr. 2002;140(4):396-403. doi: 10.1067/mpd.2002.123098. PMID: 12006952.
Kaur S, Chawla D, Pathak U, Jain S. Predischarge non-invasive risk assessment for prediction of significant hyperbilirubinemia in term and late preterm neonates. J Perinatol. 2012;32(9):716-21. doi: 10.1038/jp.2011.170. Epub 2011. PMID: 22094493.
Vohr BR, Karp D, O'Dea C, Darrow D, Coll CG, Lester BM, Brown L, Oh W, Cashore W. Behavioral changes correlated with brain-stem auditory evoked responses in term infants with moderate hyperbilirubinemia. J Pediatr. 1990 ;117(2 Pt 1):288-91. doi: 10.1016/s0022-3476(05)80549-9. PMID: 2380830.
Smith CM, Barnes GP, Jacobson CA, Oelberg DG. Auditory brainstem response detects early bilirubin neurotoxicity at low indirect bilirubin values. J Perinatol. 2004 ;24(11):730-2. doi: 10.1038/sj.jp.7211164. PMID: 15510103.
Gkoltsiou K, Tzoufi M, Counsell S, Rutherford M, Cowan F. Serial brain MRI and ultrasound findings: relation to gestational age, bilirubin level, neonatal neurologic status and neurodevelopmental outcome in infants at risk of kernicterus. Early Hum Dev. 2008 c;84(12):829-38. doi: 10.1016/j.earlhumdev.2008.09.008. Epub 2008. PMID: 18851903.
Mao J, Fu JH, Chen LY, Wang XM, Xue XD. [Changes of globus pallidus in the newborn infants with severe hyperbilirubinemia]. Zhonghua Er Ke Za Zhi. 2007;45(1):24-9. Chinese. PMID: 17349144.
Yokochi K. Magnetic resonance imaging in children with kernicterus. Acta Paediatr. 1995;84(8):937-9. doi: 10.1111/j.1651-2227.1995.tb13796.x. PMID: 7488821.
Solomon G, Labar D, Galbraith RA, Schaefer J, Kappas A. Neurophysiological abnormalities in adolescents with type I Crigler-Najjar syndrome. Electroencephalogr Clin Neurophysiol. 1990 ;76(5):473-5. doi: 10.1016/0013-4694(90)90100-x. PMID: 1699740.
Newman TB, Liljestrand P, Jeremy RJ, Ferriero DM, Wu YW, Hudes ES, Escobar GJ; Jaundice and Infant Feeding Study Team. Outcomes among newborns with total serum bilirubin levels of 25 mg per deciliter or more. N Engl J Med. 2006: 4;354(18):1889-900. doi: 10.1056/NEJMoa054244. PMID: 16672700.
Wu YW, Kuzniewicz MW, Wickremasinghe AC, Walsh EM, Wi S, McCulloch CE, Newman TB. Risk for cerebral palsy in infants with total serum bilirubin levels at or above the exchange transfusion threshold: a population-based study. JAMA Pediatr. 2015;169(3):239-46. doi: 10.1001/jamapediatrics.2014.3036. PMID: 25560920.
Johnson L, Bhutani VK. The clinical syndrome of bilirubin-induced neurologic dysfunction. Semin Perinatol. 2011;35(3):101-13. doi: 10.1053/j.semperi.2011.02.003. PMID: 21641482.
Akinpelu OV, Waissbluth S, Daniel SJ. Auditory risk of hyperbilirubinemia in term newborns: systematic review. Int J Pediatr Otorhinolaryngol. 2013;77(6):898-905. doi: 10.1016/j.ijporl.2013.03.029. Epub 2013. PMID: 23642487.
Sheykholeslami K, Kaga K. Otoacoustic emissions and auditory brainstem responses after neonatal hyperbilirubinemia. Int J Pediatr Otorhinolaryngol. 2000;52(1):65-73. doi: 10.1016/s0165-5876(99)00293-1. PMID: 10699242.
Hansen TW, Nietsch L, Norman E, Bjerre JV, Hascoet JM, Mreihil K, Ebbesen F. Reversibility of acute intermediate phase bilirubin encephalopathy. Acta Paediatr. 2009;98(10):1689-94. doi: 10.1111/j.1651-2227.2009.01409.x. Epub 2009 Jul 6. PMID: 19583707.
Newman TB, Wickremasinghe AC, Walsh EM, Grimes BA, McCulloch CE, Kuzniewicz MW. Retrospective Cohort Study of Phototherapy and Childhood Cancer in Northern California. Pediatrics. 2016 ;137(6):e20151354. doi: 10.1542/peds.2015-1354. PMID: 27217477.
Ballow M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol. 2011 Feb;127(2):315-23; quiz 324-5. doi: 10.1016/j.jaci.2010.10.030. Epub 2010 Dec 24. PMID: 21185071.
Louis D, More K, Oberoi S, Shah PS. Intravenous immunoglobulin in isoimmune haemolytic disease of newborn: an updated systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2014 Jul;99(4):F325-31. doi: 10.1136/archdischild-2013-304878. Epub 2014 Feb 10. PMID: 24514437.
Bhutani VK, Poland R, Meloy LD, Hegyi T, Fanaroff AA, Maisels MJ. Clinical trial of tin mesoporphyrin to prevent neonatal hyperbilirubinemia. J Perinatol. 2016 Jul;36(7):533-9. doi: 10.1038/jp.2016.22. Epub 2016 Mar 3. PMID: 26938918.
Strauss KA, Puffenberger EG, Carson VJ. Maple Syrup Urine Disease. 2006 [updated 2020]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2020.
Levin ML, Scheimann A, Lewis RA, Beaudet AL. Cerebral edema in maple syrup urine disease. J Pediatr. 1993; 122:167-8.
Volpe JJ, Inder TE, Darras BT, de Vries LS, du Plessis AJ, Neil JJ, Perlman J. Volpe's neurology of the newborn. Elsevier; 2017.
Blackburn PR, Gass JM, Vairo FPE, et al. Maple syrup urine disease: mechanisms and management. Appl Clin Genet. 2017;10:57-66. doi: 10.2147/TACG.S125962.
Estivill E, Sanmarti FX, Vidal R, Alvira R, Lizarraga I, Linares J. Comb-like rhythm: an EEG pattern peculiar to leucinosis. An Esp Pediatr. 1985; 22: 123-127.
Tharp BR. Unique EEG pattern (comb-like rhythm) in neonatal maple syrup urine disease. Pediatr Neurol. 1992;8:65-68.
Fariello G, Dionisi-Vici C, Orazi C, et al. Cranial ultrasonography in maple syrup urine disease. AJNR Am J Neuroradiol. 1996;17: 311-315.
Barkovich AJ. Pediatric Neuroimaging. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2005.
Jan W, Zimmerman RA, Wang ZJ, Berry GT, Kaplan PB, Kaye EM. MR diffusion imaging and MR spectroscopy of maple syrup urine disease during acute metabolic decompensation. Neuroradiology. 2003;45:393-9. doi: 10.1007/s00234-003-0955-7.
Aydın K. Nörometabolik hastalıklar: Olgularla klinik ve görüntüleme ipuçları. 1. Baskı. Kayseri. Medikal Kitapevi; 2021.
Strauss KA, Carson VJ, Soltys K, et al. Branched-chain α-ketoacid dehydrogenase deficiency (maple syrup urine disease): Treatment, biomarkers, and outcomes. Mol Genet Metab. 2020;129:193-206. doi: 10.1016/j.ymgme.2020.01.006.
Puliyanda DP, Harmon WE, Peterschmitt MJ, Irons M, Somers MJ. Utility of hemodialysis in maple syrup urine disease. Pediatr Nephrol. 2002;17:239-42. doi: 10.1007/s00467-001-0801-2.
Thompson GN, Butt WW, Shann FA, et al. Continuous venovenous hemofiltration in the management of acute decompensation in inborn errors of metabolism. J Pediatr. 1991;118:879-84. doi: 10.1016/s0022-3476(05)82198-5.
Xu J, Jakher Y, Ahrens-Nicklas RC. Brain Branched-Chain Amino Acids in Maple Syrup Urine Disease: Implications for Neurological Disorders. Int J Mol Sci. 2020;21:7490. doi: 10.3390/ijms 21207490.
Kure S, Kato K, Dinopoulos A, et al. Comprehensive mutation analysis of GLDC, AMT, and GCSH in nonketotic hyperglycinemia. Hum Mutat. 2006;27:343-52. doi: 10.1002/humu.20293.
Kish SJ, Dixon LM, Burnham WM, et al. Brain neurotransmitters in glycine encephalopathy. Ann Neurol. 1988;24:458-61. doi: 10.1002/ana.410240319.
Patel J, Zinkand WC, Thompson C, Keith R, Salama A. Role of glycine in the N-methyl-D-aspartate-mediated neuronal cytotoxicity. J Neurochem. 1990;54:849-54. doi: 10.1111/j.1471-4159.1990.tb02329.x.
Genç Sel Ç, Kılıç M, Yüksel D, et al. Nonketotic hyperglycinemia: Clinical range and outcome of a rare neurometabolic disease in a single-center. Brain Dev. 2018;40:865-875. doi: 10.1016/j.braindev.2018.06.007.
Hoover-Fong JE, Shah S, Van Hove JL, Applegarth D, Toone J, Hamosh A. Natural history of nonketotic hyperglycinemia in 65 patients. Neurology. 2004;63:1847-53. doi: 10.1212/01.wnl.0000144270.83080.29.
Van Hove JLK, Coughlin C II, Swanson M, Hennermann JB. Nonketotic Hyperglycinemia. 2002 [updated 2019]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2021.
Patay Z. Diffusion-weighted MR imaging in leukodystrophies. Eur Radiol. 2005;15:2284-303. doi: 10.1007/s00330-005-2846-2.
Krawiec C, Goyal A. Nonketotic Hyperglycinemia. 2021. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021.
Tekgul H, Serdarolu G, Karapinar B, et al. Vigabatrin caused rapidly progressive deterioration in two cases with early myoclonic encephalopathy associated with nonketotic hyperglycinemia. J Child Neurol. 2006;21:82–4.
Maines E, Piccoli G, Pascarella A, Colucci F, Burlina AB. Inherited hyperammonemias: a Contemporary view on pathogenesis and diagnosis, Expert Opinion on Orphan Drugs. 2018; 6: 105-116. doi: 10.1080/21678707.2018.1409108
Martin-Hernandez E, Aldamiz-Echevarria L, Castejon-Ponce E, et al. Urea cycle disorders in Spain: an observational, crosssectional and multicentric study of 104 cases. Orphanet J Rare Dis. 2014;9:187.
Häberle J, Burlina A, Chakrapani A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: First revision. J Inherit Metab Dis. 2019;42:1192-1230. doi: 10.1002/jimd.12100.
Marin-Valencia I, Vilaseca MA, Thio M, Garcia-Cazorla A, Artuch R, Campistol J. Assessment of the perimortem protocol in neonates for the diagnosis of inborn errors of metabolism. Eur J Paediatr Neurol. 2010;14:125-130.
Hawke L. Ammonia (plasma, blood). http://www.acb.org.uk/wha twedo/science/-AMALC.aspx. Published 2012. Accessed 26 March 2019. Urea cycle disorders—update
Özlem SN. Hacettepe İhsan Doğramaci Çocuk Hastanesi Çocuk Metabolizma Bilim Dali’nda İzlenen Üre Döngüsü Bozukluğu Olan 85 Hastanin Klinik Ve Laboratuvar Özelliklerinin Geriye Dönük İncelenmesi (Ankara, Hacettepe Üniversitesi Tıp Fakültesi Hastanesi, Uzmanlık Tezi, 2017, Sayfa 4, Tablo2)
Matsumoto S, Häberle J, Kido J, Mitsubuchi H, Endo F, Nakamura K. Urea cycle disorders-update. J Hum Genet. 2019;64:833-847. doi: 10.1038/s10038-019-0614-4.
Clancy RR, Chung HJ. EEG changes during recovery from acute severe neonatal citrullinemia. Electroencephalogr Clin Neurophysiol. 1991;78:222-227.
Wiwattanadittakul N, Prust M, Gaillard WD, et al. The utility of EEG monitoring in neonates with hyperammonemia due to inborn errors of metabolism. Mol Genet Metab. 2018;125:235-240. doi: 10.1016/j.ymgme.2018.08.011.
Nagamani SCS, Erez A, Lee B. Argininosuccinate Lyase Deficiency. 2011[updated 2019]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2021.
Sun A, Crombez EA, Wong D. Arginase Deficiency. 2004 [updated 2020]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2021.
Bireley WR, Van Hove JL, Gallagher RC, Fenton LZ. Urea cycle disorders: brain MRI and neurological outcome. Pediatr Radiol. 2012;42:455-62. doi: 10.1007/s00247-011-2253-6.
Takanashi J, Barkovich AJ, Cheng SF, et al. Brain MR imaging in neonatal hyperammonemic encephalopathy resulting from proximal urea cycle disorders. AJNR Am J Neuroradiol. 2003;24:1184-7.
Kido J, Nakamura K, Mitsubuchi H, et al. Long-term outcome and intervention of urea cycle disorders in Japan. J Inherit Metab Dis. 2012;35:777-785.
Cunningham SC, Spinoulas A, Carpenter KH, Wilcken B, Kuchel PW, Alexander IE. AAV2/8-mediated correction of OTC deficiency is robust in adult but not neonatal Spf(ash) mice. Mol Ther. 2009;17:1340- 6.
Chowdhury JR, Chowdhury NR, Strom SC, Kaufman SS, Horslen S, Fox IJ. Human hepatocyte transplantation: gene therapy and more? Pediatrics. 1998;102:647-8.
Ozand PT, Gascon GG. Organic acidurias: a review—part 1. J Child Neurol 1991;6(3):196–219.
Volpe JJ. Neurology of the newborn. 6th edition. Philadelphia: Elsevier Ltd, Oxford; 2018.
Shchelochkov OA, Carrillo N, Venditti C. Propionic Acidemia. 2012 May 17 [updated 2016 Oct 6]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2021.
. Grünert SC, Müllerleile S, De Silva L, et al. Propionic acidemia: clinical course and outcome in 55 pediatric and adolescent patients. Orphanet J Rare Dis 2013;8:6.
Dave P, Curless RG, Steinman L. Cerebellar hemorrhage complicating methylmalonic and propionic acidemia. Arch Neurol. 1984;41:1293-1296.
Reddy N, Calloni SF, Vernon HJ, Boltshauser E, Huisman TAGM, Soares BP. Neuroimaging findings of organic acidemias and aminoacidopathies. Radiographics. 2018;38(3):912-931. doi: 10.1148/rg.2018170042.
Forny P, Hörster F, Ballhausen D, et al. Guidelines for the diagnosis and management of methylmalonic acidaemia and propionic acidaemia: First revision. J Inherit Metab Dis. 2021;44(3):566-592. doi: 10.1002/jimd.12370.
Zhou X, Cui Y, Han J. Methylmalonic acidemia: Current status and research priorities. Intractable Rare Dis Res. 2018;7(2):73-78. doi: 10.5582/irdr.2018.01026.
Fraser JL, Venditti CP. Methylmalonic and propionic acidemias: clinical management update. Curr Opin Pediatr. 2016;28(6):682-693. doi: 10.1097/MOP.0000000000000422.
Aydın K. Nörometabolik hastalıklar: Olgularla klinik ve görüntüleme ipuçları. 1. Baskı. Kayseri. Medikal Kitapevi; 2021.
Pavlu-Pereira H, Silva MJ, Florindo C, et al. Pyruvate dehydrogenase complex deficiency: updating the clinical, metabolic and mutational landscapes in a cohort of Portuguese patients. Orphanet J Rare Dis. 2020 Oct 22;15(1):298. doi: 10.1186/s13023-020-01586-3.
Saijo H, Tanaka H, Ito J, et al. Pyruvate dehydrogenase complex deficiency with multiple minor anomalies. Acta Paediatr Jpn. 1997;39(2):230-2. doi: 10.1111/j.1442-200x.1997.tb03588.x.
Mhanni AA, Rockman-Greenberg C, Ryner L, Bunge M. Prenatal onset of the neuroradiologic phenotype of pyruvate carboxylase deficiency due to homozygous PC c.1828G > A mutations. JIMD Rep. 2021;61(1):42-47. doi: 10.1002/jmd2.12235.
Wang D, De Vivo D. Pyruvate Carboxylase Deficiency. 2009 Jun 2 [Updated 2018 Mar 1]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2021.
Garcia-Cazorla A, Rabier D, Touati G, et al. Pyruvate carboxylase deficiency: metabolic characteristics and new neurological aspects. Ann Neurol. 2006;59:121-127.
DiMauro S, De Vivo DC. Diseases of carbohydrate, fatty acid and mitochondrial metabolism. In: Siegel J, ed. Basic Neurochemistry: Molecular, Cellular and Medical Aspects. Philadelphia, PA: Lippincott-Raven Publishers; 1999:841-63.
Roe CR, Mochel F. Anaplerotic diet therapy in inherited metabolic disease: therapeutic potential. J Inherit Metab Dis. 2006;29:332–40.
Ahmad A, Kahler SG, Kishnani PS, et al. Treatment of pyruvate carboxylase deficiency with high doses of citrate and aspartate. Am J Med Genet. 1999;87:331–8.
Mochel F. Triheptanoin for the treatment of brain energy deficit: a 14-year experience. J Neurosci Res. 2017;95:2236-43.
Mochel F, DeLonlay P, Touati G, et al. Pyruvate carboxylase deficiency: clinical and biochemical response to anaplerotic diet therapy. Mol Genet Metab. 2005;84:305–12.
Nyhan WL, Khanna A, Barshop BA, et al. Pyruvate carboxylase deficiency--insights from liver transplantation. Mol Genet Metab. 2002;77:143–9.
Khan A, Zahid B, Khan S, Ahmad SA. Isovaleric Acidemia: A Rare Case of an Inborn Error of Metabolism. Cureus. 2020:29;12(2):e7150. doi: 10.7759/cureus.7150.
Vockley J, Ensenauer R. Isovaleric acidemia: new aspects of genetic and phenotypic heterogeneity. Am J Med Genet C Semin Med Genet. 2006: 15;142C(2):95-103. doi: 10.1002/ajmg.c.30089.
Alshumrani GA, Patay Z. Brain magnetic resonance imaging and proton MR spectroscopic findings after metabolic crisis in 3-methylcrotonylglycinuria. Ann Saudi Med 2015;35(1):64–68.
van der Knaap MS, Bakker HD, Valk J. MR imaging and proton spectroscopy in 3-hydroxy-3-methylglutaryl coenzyme A lyase deficiency. AJNR Am J Neuroradiol 1998;19(2):378–382. 65.
Yalçinkaya C, Dinçer A, Gündüz E, Fiçicioğlu C, Koçer N, Aydin A. MRI and MRS in HMG-CoA lyase deficiency. Pediatr Neurol 1999;20(5):375–380.
Munoz MA, Jurczyluk J, Simon A, et al. Defective Protein Prenylation in a Spectrum of Patients With Mevalonate Kinase Deficiency. Front Immunol. 2019;10:1900. doi: 10.3389/fimmu.2019.01900.
Haas D, Hoffmann GF. Mevalonate kinase deficiencies: from mevalonic aciduria to hyperimmunoglobulinemia D syndrome. Orphanet J Rare Dis. 2006;1:13. doi: 10.1186/1750-1172-1-13.
Grünert SC, Sass JO. 2-methylacetoacetyl-coenzyme A thiolase (beta-ketothiolase) deficiency: one disease-two pathways. Orphanet J Rare Dis. 2020;28;15(1):106. doi: 10.1186/s13023-020-01357-0.
Shekhawat PS, Matern D, Strauss AW. Fetal fatty acid oxidation disorders, their effect on maternal health and neonatal outcome: impact of expanded newborn screening on their diagnosis and management. Pediatr Res. 2005;57(5 Pt 2):78R-86R. doi: 10.1203/01.PDR.0000159631.63843.3E.
Coşkun T, Tokatli A, Ozalp I. Inborn errors of biotin metabolism. Clinical and laboratory features of eight cases. Turk J Pediatr. 1994;36:267-78.
Donti TR, Blackburn PR, Atwal PS. Holocarboxylase synthetase deficiency pre and post newborn screening. Mol Genet Metab Rep. 2016;7:40-4. doi: 10.1016/j.ymgmr.2016.03.007.
Bandaralage SP, Farnaghi S, Dulhunty JM, Kothari A. Antenatal and postnatal radiologic diagnosis of holocarboxylase synthetase deficiency: a systematic review. Pediatr Radiol. 2016;46(3):357-64. doi: 10.1007/s00247-015-3492-8.
Wilson CJ, Myer M, Darlow BA, et al. Severe holocarboxylase synthetase deficiency with incomplete biotin responsiveness resulting in antenatal insult in samoan neonates. J Pediatr. 2005;147(1):115-8. doi: 10.1016/j.jpeds.2005.03.006.
Kasapkara ÇS, Akar M, Özbek MN, et al. Mutations in BTD gene causing biotinidase deficiency: a regional report. J Pediatr Endocrinol Metab. 2015;28(3-4):421-4.
Saleem H, Simpson B. Biotinidase Deficiency. 2021 Aug 14. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. PMID: 32809442.
Canda E, Kalkan Uçar S, Çoker M. Biotinidase Deficiency: Prevalence, Impact And Management Strategies. Pediatric Health Med Ther. 2020;11:127-133.
Pindolia K, Chen J, Cardwell C, Cui X, Chopp M, Wolf B. Neurological deficits in mice with profound biotinidase deficiency are associated with demylination and axonal degeneration. Neurobiol Dis. 2012;47(3):428-35.
Canda E, Yazici H, Er E, et al. Single center experience of biotinidase deficiency: 259 patients and six novel mutations. J Pediatr Endocrinol Metab. 2018;31(8):917–926. doi:10.1515/jpem-2018-0148
Odhaib SA, Mansour AA, Haddad NS. How biotin induces misleading results in thyroid bioassays: case series. Cureus. 2019;11(5):e4727.
Doğan M, Bektas MS, Okur M, et al. Glutarik Asidüri Tip 2. Türkiye Çocuk Hast. Derg. / Turkish J. Pediatr. Dis. 2012;6(3):171-175.
Prasun P. Multiple Acyl-CoA Dehydrogenase Deficiency. 2020 Jun 18. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Mirzaa GM, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2022. PMID: 32550677.
Boy N, Mühlhausen C, Maier EM, et al. Proposed recommendations for diagnosing and managing individuals with glutaric aciduria type I: second revision. J Inherit Metab Dis. 2017;40(1):75-101. doi: 10.1007/s10545-016-9999-9.
Yapicioğlu H, Satar M, Tutak E, Narli N, Topaloğlu AK. A newborn infant with generalized glutathione synthetase deficiency. Turk J Pediatr. 2004;46(1):72-5.
Misko AL, Liang Y, Kohl JB, Eichler F. Delineating the phenotypic spectrum of sulfite oxidase and molybdenum cofactor deficiency. Neurol Genet. 2020;6(4):e486. doi: 10.1212/NXG.0000000000000486.
Zaki MS, Selim L, El-Bassyouni HT, et al. Molybdenum cofactor and isolated sulphite oxidase deficiencies: Clinical and molecular spectrum among Egyptian patients. Eur J Paediatr Neurol. 2016;20(5):714-22. doi: 10.1016/j.ejpn.2016.05.011.
